A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients With Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

N
Nabil Adra, MD

Primary Investigator

Overview

This randomized phase III trial compares nephrectomy (surgery to remove a kidney or part of a kidney) with or without nivolumab in treating patients with kidney cancer that is limited to a certain part of the body (localized).

Description

The purpose of this study is to compare recurrence-free survival (RFS) between patients with locally advanced renal cell carcinoma randomly assigned to perioperative nivolumab in conjunction with radical or partial nephrectomy with patients randomized to surgery alone.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Renal Cell Carcinoma,renal cancer,kidney cancer
  • Age: Between 18 Years - 100 Years
  • Gender: All

Inclusion Criteria
In order to be eligible to take part in this trial, patients must meet the following criteria:

  • 18 years or older
  • Patients with newly diagnosed higher risk RCC of any histology including sarcomatoid

For a full list of participation criteria, please visit clinicaltrials.gov.


Additional Information:
Participants will not be paid for their participation.

Updated on 20 Nov 2022. Study ID: 1803706029 (EA8143)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center